Sangamo and Astellas Announce Capsid License Agreement to Deliver Genomic Medicine for Neurological Diseases

Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference

BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 4, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on Monday, January 10 th at 7:00 a.m. Eastern Time .